Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

New developments in anti-malarial target candidate and product profiles.

Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC.

Malar J. 2017 Jan 13;16(1):26. doi: 10.1186/s12936-016-1675-x. Review. Erratum in: Malar J. 2017 Apr 18;16(1):151.

2.

A common strategy for initiating the transition from proliferation to quiescence.

Miles S, Breeden L.

Curr Genet. 2017 May;63(2):179-186. doi: 10.1007/s00294-016-0640-0. Epub 2016 Aug 20. Review.

PMID:
27544284
3.

We all need to know about HIV cure research: a case report.

Davies O, Fox J.

J Virus Erad. 2015 Apr 1;1(2):131-2.

4.

Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.

Benhar M, Shytaj IL, Stamler JS, Savarino A.

J Clin Invest. 2016 May 2;126(5):1630-9. doi: 10.1172/JCI85339. Epub 2016 May 2. Review.

5.

Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.

Lee WS, Richard J, Lichtfuss M, Smith AB 3rd, Park J, Courter JR, Melillo BN, Sodroski JG, Kaufmann DE, Finzi A, Parsons MS, Kent SJ.

J Virol. 2015 Dec 9;90(4):2021-30. doi: 10.1128/JVI.02717-15.

6.
7.

Epigenetic control of HIV-1 post integration latency: implications for therapy.

Kumar A, Darcis G, Van Lint C, Herbein G.

Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015. Review.

8.

Human CD4+ T cells require exogenous cystine for glutathione and DNA synthesis.

Levring TB, Kongsbak M, Rode AK, Woetmann A, Ødum N, Bonefeld CM, Geisler C.

Oncotarget. 2015 Sep 8;6(26):21853-64.

9.

Global Promoter Targeting of a Conserved Lysine Deacetylase for Transcriptional Shutoff during Quiescence Entry.

McKnight JN, Boerma JW, Breeden LL, Tsukiyama T.

Mol Cell. 2015 Sep 3;59(5):732-43. doi: 10.1016/j.molcel.2015.07.014. Epub 2015 Aug 20.

10.

The macrophage: a therapeutic target in HIV-1 infection.

Kumar A, Herbein G.

Mol Cell Ther. 2014 Apr 2;2:10. doi: 10.1186/2052-8426-2-10. eCollection 2014. Review.

11.

Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.

Jønsson KL, Tolstrup M, Vad-Nielsen J, Kjær K, Laustsen A, Andersen MN, Rasmussen TA, Søgaard OS, Østergaard L, Denton PW, Jakobsen MR.

Antimicrob Agents Chemother. 2015 Jul;59(7):3984-94. doi: 10.1128/AAC.00574-15. Epub 2015 Apr 20.

12.

Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.

Lu HK, Gray LR, Wightman F, Ellenberg P, Khoury G, Cheng WJ, Mota TM, Wesselingh S, Gorry PR, Cameron PU, Churchill MJ, Lewin SR.

PLoS One. 2014 Nov 19;9(11):e113341. doi: 10.1371/journal.pone.0113341. eCollection 2014.

13.

Measuring glutathione redox potential of HIV-1-infected macrophages.

Bhaskar A, Munshi M, Khan SZ, Fatima S, Arya R, Jameel S, Singh A.

J Biol Chem. 2015 Jan 9;290(2):1020-38. doi: 10.1074/jbc.M114.588913. Epub 2014 Nov 18.

14.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

15.

Selective HDAC inhibition for the disruption of latent HIV-1 infection.

Barton KM, Archin NM, Keedy KS, Espeseth AS, Zhang YL, Gale J, Wagner FF, Holson EB, Margolis DM.

PLoS One. 2014 Aug 19;9(8):e102684. doi: 10.1371/journal.pone.0102684. eCollection 2014.

16.

The 20th International AIDS Conference: where do we go from here?

Wainberg MA, Kippax S, Bras M, Salif Sow P.

J Int AIDS Soc. 2014 Jul 18;17:19331. doi: 10.7448/IAS.17.1.19331. eCollection 2014. No abstract available.

17.

Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.

Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, Tanuri A, Gama L.

PLoS One. 2014 May 14;9(5):e97257. doi: 10.1371/journal.pone.0097257. eCollection 2014.

18.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

19.

Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.

Manson McManamy ME, Hakre S, Verdin EM, Margolis DM.

Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551. Review.

20.

A cure for AIDS: a matter of timing?

Shytaj IL, Savarino A.

Retrovirology. 2013 Nov 22;10:145. doi: 10.1186/1742-4690-10-145. Review.

Supplemental Content

Support Center